Reprogramming mitochondrial homeostasis in renal ischemia–reperfusion injury
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2025.112294 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cellular Signalling, 2026. Verfasst von Kangyu Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou Uni…. Hauptthemen laut MEDLINE: Reperfusion Injury, Mitochondria, Acute Kidney Injury, Homeostasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 108 Literaturangaben. Gefördert von: Science and Technology Program of Gansu Province, Lanzhou City Science and Technology Bureau, National Natural Science Foundation of China.
Abstract (Originalsprache)
Acute kidney injury (AKI) caused by renal ischemia-reperfusion injury (RIRI) is primarily a mitochondrial disorder characterized by disrupted dynamics, impaired biogenesis, and defective quality control. Excessive DRP1-mediated fission, suppression of the AMPK-SIRT-PGC-1α axis, and failure of the PINK1-Parkin mitophagy system converge to drive tubular dysfunction and ferroptosis. Here, we integrate recent insights into a "mitochondrial reprogramming" framework encompassing three axes-dynamic remodeling, metabolic renewal, and proteostatic reinforcement. Therapeutic strategies targeting these axes, such as DRP1 inhibition, AMPK-SIRT-PGC-1α activation, and reinforcement of mitophagy and MAM integrity by agents like melatonin, puerarin, or Schisandrin B, have shown promise in restoring mitochondrial resilience. Furthermore, mitochondrial biomarkers and imaging tools (mtDNA, mitochondrial peptides, [18F]BCPP-EF PET) may enable phenotype-guided interventions. This review outlines the "RIRI-Mitochondria-AKI-CKD continuum," emphasizing that mitochondrial maladaptation bridges acute injury and chronic fibrosis, highlighting mitochondria as precision therapeutic targets in AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China; Institute of Urology, Gansu Province Clinical…
- Department of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
- Department of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Electronic address: 1592944310@qq.com.
- Department of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Electronic address: ery_yangli@lzu.edu.cn.
Förderung
- Science and Technology Program of Gansu Province
- Lanzhou City Science and Technology Bureau
- National Natural Science Foundation of China
Zitieren
APA
Wang, K., Wang, H., Zhang, Y., Zhang, Z., Wang, L., Yang, J., Man, J., & Yang, L. (2026). Reprogramming mitochondrial homeostasis in renal ischemia–reperfusion injury. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112294
Vancouver
Wang K, Wang H, Zhang Y, Zhang Z, Wang L, Yang J, et al. Reprogramming mitochondrial homeostasis in renal ischemia–reperfusion injury. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2025.112294
BibTeX
@article{Wang2026,
author = {Wang, Kangyu and Wang, Hao and Zhang, Yalong and Zhang, Zijian and Wang, Li and Yang, Jianwei and Man, Jiangwei and Yang, Li},
title = {Reprogramming mitochondrial homeostasis in renal ischemia–reperfusion injury},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2025.112294}
}
EUVIMED